Dr Fazel Shabanpoor is Florey Research Fellow at the Florey Institute of Neuroscience and Mental Health, University of Melbourne. He is a medicinal biochemist with expertise in peptide and oligonucleotides drug development. In 2011, following completion of his PhD, he received a CJ. Martin Fellowship from National Health and Medical Research Council of Australia and moved to the UK to continue his post-doctoral training at two of the world's most renowned research institutes, MRC Laboratory of Molecular Biology in Cambridge and Department of Physiology, Anatomy and Genetics at the University of Oxford.
During his time in UK, he focused on development of therapeutic peptides and antisense oligonucleotides (ASOs) for the treatment of neurodegenerative diseases. Since his return from UK, he has established antisense drug development platform at the Florey Institute and the focus of his current research is:
• Development of antisense targeting several genes (SOD1, C9ORF72, Ataxin-2) as personalised genetic medicine for ALS patients.
• Development of peptides to clear toxic protein aggregates from motor neurons as potential therapy for MND.
• Development of peptide-based drug delivery platform to deliver therapeutic ASOs into the brain and spinal cord.
Brain health affects all Australians. You can support our research by making a donation or a bequest.